Following its initial public offering last month, Cingulate Inc.
(NASDAQ: CING), a clinical-stage biopharmaceutical company
utilizing its proprietary Precision Timed Release™ (PTR™) drug
delivery platform technology to build and advance a pipeline of
next-generation pharmaceutical products, publicly announced today
the appointments of Curt Medeiros and Gregg Givens to its Board of
Directors. Officially, Medeiros and Givens joined Cingulate’s board
in September.
“We are excited to have Curt and Gregg on the
Cingulate Board of Directors,” said Shane J. Schaffer, PharmD,
Chairman and Chief Executive Officer (CEO) of Cingulate. “Curt’s
background in high-growth healthcare companies with relationships
across the payer, provider, and life science markets, and Gregg’s
two decades of public company finance experience, complement the
experience and skills of our current Board and management team. We
are benefitting from their fresh perspectives as we continue to
advance our innovative product candidates, revitalize patient care
and deliver value to our investors.”
“Behavioral health is becoming a high priority
for the U.S. and global healthcare system, however significant
challenges persist for patients, physicians, and families living
with and caring for individuals with Attention
Deficit/Hyperactivity Disorder (ADHD),” said Medeiros, former Chief
Operating Officer (COO) and Senior Vice President of Optum Life
Sciences. “I am impressed with Cingulate’s commitment to this
underserved population and progress in developing its two ADHD
product candidates, which we believe will simplify the daily
management of ADHD, and the future of its broader pipeline. I am
deeply committed to Cingulate’s mission and vision and will support
the Company’s leadership and talented employees to develop these
important treatments and drive growth.”
“I am pleased to join the Cingulate Board and
believe it has a significant opportunity to address the
long-standing unmet needs of patients with ADHD,” said Givens, who
most recently served as Senior Vice President, Chief Financial
Officer (CFO) and Treasurer for publicly traded DST Systems Inc.
“Cingulate, its product candidates, and drug pipeline are on an
exciting trajectory. I look forward to working with the Board and
management team to continue executing on Cingulate’s clinical and
business milestones for the benefit of patients, employees, and
investors.”
Curt Medeiros, current CEO and
Board member of software company Ovation.io, has more than 20 years
of healthcare leadership experience throughout the payer, provider,
and life science markets. He worked for nearly 10 years at Optum, a
leading information and technology-enabled health services business
that is part of UnitedHealth Group, including several leadership
roles with significant P&L responsibility. From 2014 to 2016,
he served as COO and Senior Vice President of Optum Life Sciences,
which drives client value by providing best-in-class real-world
data, analytics, consulting, and collaborations aimed at improving
the health care system for all stakeholders. From 2016 to 2019,
Medeiros served as President of both Optum Analytics and Optum
Advanced Data & Analytics, overseeing businesses that grew to
1,200 employees and served the analytical needs of external payers,
providers, and life science companies.
Most recently, Medeiros served as President and
COO of publicly traded Ontrak Inc., a leading AI-powered and
telehealth-enabled healthcare company, from December 2019 to June
2021. He has an MBA from Harvard Business School and a B.S. in
chemical engineering from the Massachusetts Institute of
Technology.
Gregg Givens has more than 35
years of financial and operational leadership experience across the
global fintech and healthcare processing, manufacturing, asset
management, and real estate industries. For more than two decades,
Givens served in finance and accounting leadership roles at DST
Systems Inc., a provider of advisory, technology, and operations
outsourcing to the financial and healthcare industries, with 16,000
employees worldwide. From 2014 to 2018, Givens served as the
company’s Senior Vice President, CFO, and Treasurer through its
sale to SS&C Technologies. Prior to DST, Givens, a certified
public accountant, worked for nearly 15 years at
PricewaterhouseCoopers. He has a BSACC from the University of
Missouri-Columbia.
About
Cingulate®
Cingulate Inc. (NASDAQ: CING), is a clinical-stage
biopharmaceutical company utilizing its proprietary Precision Timed
Release™ (PTR™) drug delivery platform technology to build and
advance a pipeline of next-generation pharmaceutical products,
designed to improve the lives of patients suffering from frequently
diagnosed conditions characterized by burdensome daily dosing
regimens and suboptimal treatment outcomes. With an initial focus
on the treatment of Attention Deficit/Hyperactivity Disorder
(ADHD), Cingulate is identifying and evaluating additional
therapeutic areas where PTR technology may be employed to develop
future product candidates, including to treat anxiety
disorders.
Cingulate is headquartered in Kansas City. For
more information visit Cingulate.com
Forward-Looking Statements
This press release contains “forward-looking
statements” within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. These forward-looking
statements include all statements, other than statements of
historical fact, regarding our current views and assumptions with
respect to future events regarding our business, including
statements with respect to our plans, assumptions, expectations,
beliefs and objectives with respect to product development,
clinical studies, clinical and regulatory timelines, market
opportunity, competitive position, business strategies, potential
growth opportunities and other statements that are predictive in
nature.
These statements are generally identified by the
use of such words as “may,” “could,” “should,” “would,” “believe,”
“anticipate,” “forecast,” “estimate,” “expect,” “intend,” “plan,”
“continue,” “outlook,” “will,” “potential” and similar statements
of a future or forward-looking nature. Readers are cautioned that
any forward-looking information provided by us or on our behalf is
not a guarantee of future performance. Actual results may differ
materially from those contained in these forward-looking statements
as a result of various factors disclosed in our filings with the
Securities and Exchange Commission (SEC), including the “Risk
Factors” section of our prospectus filed with the SEC on
December 9, 2021. All forward-looking statements speak only as
of the date on which they are made and we undertake no duty to
update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise, except to
the extent required by law.
Contacts:
Investor Relations Thomas
Dalton Head of Investor & Public Relations, Cingulate,
Inc.TDalton@cingulate.com913-942-2301
Andy Brimmer / Amy FengJoele Frank, Wilkinson
Brimmer Katcherabrimmer@joelefrank.com afeng@joelefrank.com
212-355-4449
Media RelationsMelyssa
WeibleElixir Health Public
Relationsmweible@elixirhealthpr.com201-723-5805
CING-US-100-0123
Cingulate (NASDAQ:CING)
Historical Stock Chart
From Jun 2024 to Jul 2024
Cingulate (NASDAQ:CING)
Historical Stock Chart
From Jul 2023 to Jul 2024